|ECHA InfoCard||100.118.791 |
|Chemical and physical data|
|Molar mass||253.34 g/mol g·mol−1|
|3D model (JSmol)|
The dextrorotary (R)-(+)-enantiomer is the most pharmacologically active, although a variety of related derivatives have been studied.
Side effects including chest pain (suggestive of possible cardiovascular toxicity) have been seen following recreational use of diphenylprolinol, although it was combined with glaucine in a party pill product, thus making it impossible to say for certain which drug was responsible.
- Wood DM, et al. (2008). "Detection of the novel recreational drug Diphenyl-2-pyrrolidinemethanol (D2PM) sold legally in combination with 1-Benzylpiperzaine (BZP)". Clinical Toxicology. 46: 393. doi:10.1080/15563650802071703. PMID 18568796.
- Davies S. Drug Trends and New Designer Drugs. St George's University of London. 6 November 2008.
- US patent 5925666, Paul F. Jackson et al., "Pharmaceutical compositions and methods for treating compulsive disorders using pyrrolidine derivatives"
- Lidder, S; Dargan, P; Sexton, M; Button, J; Ramsey, J; Holt, D; Wood, D (2008). "Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol D2PM)". Journal of Medical Toxicology. 4 (3): 167–9. doi:10.1007/bf03161195. PMC 3550040. PMID 18821489.
- Corey, E. J.; Bakshi, R. K.; Shibata S. (1987). "Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines Mechanism and synthetic implications". J. Am. Chem. Soc. 109 (18): 5551–5553. doi:10.1021/ja00252a056. ISSN 0002-7863.